Wharton professor on the employer Covid vaccine requirement dilemma
Nancy Rothbard, chair of the Management Department at the University of Pennsylvania’s Wharton School, joined “Squawk Box” on Thursday to
Read more
Squawk Box U.S.
AstraZeneca vaccine found to be 79% effective in U.S. trial
The findings of a large U.S. trial have shown that the coronavirus vaccine developed by AstraZeneca and the University of
Read more
Pfizer CEO Albert Bourla on Covid-19 vaccine manufacturing outlook
Pfizer CEO Albert Bourla told CNBC’s “Squawk Box” Tuesday that the company plans to increase coronavirus vaccine production this year,
Read more
Former FDA chief on Pfizer Covid-19 vaccine’s ability to neutralize variants
A coronavirus vaccine developed by Pfizer and BioNTech appears to be effective against a key mutation in the more infectious
Read more
Johnson & Johnson starts phase 3 coronavirus vaccine trial
Johnson & Johnson has begun its phase three trial testing its potential coronavirus vaccine, the pharmaceutical company announced Wednesday. CNBC’s
Read more
Moderna CEO: We expect to know if Covid-19 vaccine works in November
Moderna should have enough data from its late-stage trial to know whether its coronavirus vaccine works in November, CEO Stephane
Read more
General Covid-19 vaccine approval likely a 2021 event: Fmr. FDA chief
Dr. Scott Gottlieb, member of the boards of Pfizer and biotech company Illumina and former FDA commissioner, joins “Squawk Box”
Read more
Novavax CEO on $1.6 billion in federal funding, Covid-19 vaccine progress and more
The U.S. government has awarded Novavax $1.6 billion to support the late-stage development and scale up in manufacturing of its
Read more
Expect Covid-19 vaccine to be seasonal like the flu shot: Former FDA chief
White House health advisor Dr. Anthony Fauci said he worries about the “durability” of a potential coronavirus vaccine, saying there’s
Read more
Gilead seems to be in the lead for coronavirus vaccine, strategist says
Amid Monday’s sell-off, the biotech sector seemed to fare well on prospects of a coronavirus treatment. Jared Holz, health-care equity
Read more